[Dinutuximab for patients with high-risk neuroblastoma]

Tapia López E, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A.
Record ID 32018001416
Original Title: Dinutuximab en pacientes con neuroblastoma de alto riesgo
Authors' recomendations: CONCLUSIONS Moderate quality evidence suggests that dinutuximab use in combination with granulocyte-macrophage colony-stimulating factor, interleukin 2 and 13-cis-retinoic acid could prolong overall survival and event-free survival in patients with high-risk neuroblastoma showing partial response to induction therapy and who receive stem-cell transplant. The most commonly reported adverse events were neuropathic pain, capillary escape syndrome and fever. The clinical practice guideline identified considers dinutuximab use for postconsolidation therapy, although it mentions that because of its high cost it is not very affordable. The coverage policy identified from a United States health sponsor covers it as postconsolidation therapy. In Argentina, this technology has not been approved so far and no cost-effectiveness studies assessing it have been identified.
Project Status: Completed
Year Published: 2017
URL for published report: https://www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Neuroblastoma
  • Antibodies, Monoclonal
  • Antineoplastic Agents
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.